Clinical Trials Logo

Breast Tumor clinical trials

View clinical trials related to Breast Tumor.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05191004 Withdrawn - Breast Cancer Clinical Trials

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

NUV-422-03 is a randomized, non-comparative Phase 1/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with fulvestrant relative to NUV-422 monotherapy and fulvestrant monotherapy. The study population is comprised of adults with HR+HER2- aBC. Patients will self-administer NUV-422 orally in 28-day cycles and receive 500 mg fulvestrant intramuscularly (IM) on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT02725658 Withdrawn - Breast Tumor Clinical Trials

Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI

Start date: December 2015
Phase: N/A
Study type: Interventional

The purpose of this research study is to help us learn if an experimental imaging device called Diffuse Optical Spectroscopic Imaging (DOSI) can monitor tumor shrinkage during chemotherapy treatment and can predict if the tumor will respond to chemotherapy before the end of the treatment. This study will also help us understand the biological reason for how DOSI works.

NCT ID: NCT02470819 Withdrawn - Clinical trials for Metastatic Breast Cancer

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Start date: March 2014
Phase: N/A
Study type: Interventional

The primary objective is to examine the impact on progression-free survival of targeted therapy for breast cancer suggested by proteomic and genomic profiling.

NCT ID: NCT02340468 Withdrawn - Breast Tumor Clinical Trials

Breast Tumor Oxygenation During Exercise

Start date: April 2015
Phase:
Study type: Observational

In the field of cancer treatment, it is generally accepted that the enhancement of oxygen delivery to tumors can augment the effect of anti-cancer therapies. In the case of chemotherapy, this enhancement might lead to a larger amount of a given dose of treatment reaching the tumor and having an effect.